公开(公告)号：US10717736B2

公开(公告)日：2020-07-21

申请号：US16347826

申请日：2017-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guohua Zhao ,  James Mignone

IPC: C07D471/04 ,  A61K31/4375 ,  A61P1/16 ,  A61P13/12 ,  A61P11/00 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20170114054A1

公开(公告)日：2017-04-27

申请号：US15316853

申请日：2015-06-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  James Mignone ,  Wei Wang

IPC: C07D417/14 ,  C07D213/82 ,  A61K31/4418 ,  C07D413/04 ,  A61K31/4439 ,  C07D401/04 ,  C07D417/04 ,  C07D213/80 ,  C07D409/04 ,  C07D401/12 ,  A61K31/444 ,  C07D401/14 ,  C07D413/12 ,  A61K45/06 ,  C07D213/74 ,  C07D405/04 ,  C07D409/14

CPC classification number: A61K31/4418 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/444 ,  A61K45/06 ,  C07D213/74 ,  C07D213/80 ,  C07D213/82 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US20190256512A1

公开(公告)日：2019-08-22

申请号：US16347826

申请日：2017-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guohua Zhao ,  James Mignone

IPC: C07D471/04 ,  A61P11/00 ,  A61P13/12 ,  A61P1/16 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US09974778B2

公开(公告)日：2018-05-22

申请号：US15316853

申请日：2015-06-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  James Mignone ,  Wei Wang

IPC: A61K31/4418 ,  C07D417/04 ,  C07D417/14 ,  C07D409/14 ,  C07D213/82 ,  C07D413/04 ,  A61K31/4439 ,  C07D401/04 ,  C07D213/80 ,  C07D409/04 ,  C07D401/12 ,  A61K31/444 ,  C07D401/14 ,  C07D413/12 ,  A61K45/06 ,  C07D213/74 ,  C07D405/04 ,  A61K31/4412

CPC classification number: A61K31/4418 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/444 ,  A61K45/06 ,  C07D213/74 ,  C07D213/80 ,  C07D213/82 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US11292802B2

公开(公告)日：2022-04-05

申请号：US16761286

申请日：2018-11-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guohua Zhao ,  James Mignone

IPC: A61K31/4985 ,  C07D487/04 ,  C07D519/00

Abstract: The disclosure relates to compounds of formula I: Formula I which inhibit αV-containing integrins, and includes pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders.